Neurogenx is not an outright hoax, but its marketing claims go well beyond what independent clinical evidence supports. The company offers a branded electrical nerve stimulation treatment for peripheral neuropathy, primarily targeting people with diabetic nerve pain, numbness, and tingling. While electrical stimulation for neuropathy is a real area of medical research with some promising results, Neurogenx as a specific branded protocol has not been validated by the kind of large, independent, peer-reviewed trials that mainstream medical guidelines require.
What Neurogenx Actually Is
Neurogenx centers use a form of high-frequency electrical stimulation delivered through electrodes placed on the skin. The treatment typically involves two back-to-back 20-minute sessions, sometimes combined with a low-dose local anesthetic injection during the first several visits. The company markets this as “electronic signal treatment” or “electrochemical treatment” and positions it as a way to restore nerve function rather than simply mask pain.
The treatment is delivered over a series of office visits, often dozens of sessions over several weeks or months. This adds up. Most patients pay out of pocket because major insurance carriers do not cover the treatment. BlueCross BlueShield of Tennessee, for example, classifies high-frequency electrical stimulation pulses for pain as lacking sufficient evidence, which is a common stance among insurers.
What the Research Shows About Electrical Stimulation
Here’s where things get nuanced. Electrical stimulation for neuropathy is not made up. Multiple peer-reviewed studies, compiled in a review published in the Journal of Diabetes Science and Technology, show that various forms of electrical nerve stimulation can reduce neuropathy symptoms. In one controlled study, patients receiving percutaneous electrical nerve stimulation saw pain scores drop from 6.2 to 2.5 on a 10-point scale, while the sham group barely changed (6.4 to 6.3). Another study found that 73% of participants reported improvement in neuropathic symptoms after four weeks of transcutaneous electrical nerve stimulation, with measurable reductions in burning, tingling, numbness, and sleep disruption.
High-frequency stimulation, which is closer to what Neurogenx claims to use, performed well in at least one head-to-head comparison. In that study, 80% of patients receiving high-frequency stimulation were classified as responders (meaning at least one symptom improved by three or more points), compared with just 33% in the standard stimulation group. For painful neuropathy specifically, the response rate was 69% versus 25%.
Another study using frequency-modulated electromagnetic stimulation found that patients improved on objective nerve function tests, not just self-reported pain. Their ability to detect touch with fine filaments improved significantly, while the placebo group showed no change. Daytime pain scores dropped by about 30% in the treatment group and stayed flat in the placebo group.
So the general concept of using electrical signals to treat neuropathy has real science behind it. The problem is that these studies tested specific, well-defined stimulation protocols under controlled conditions. They did not test the Neurogenx branded protocol specifically.
The Gap Between the Science and the Brand
This is the critical distinction. Neurogenx markets itself using language that implies its treatment is clinically proven, often citing success rates of 87% or higher. But those numbers come from the company’s own internal data, not from independent, blinded, placebo-controlled trials published in peer-reviewed journals. In evidence-based medicine, that difference matters enormously. Internal data is collected by people who have a financial interest in the results, without the safeguards that independent research requires.
The company has also referenced FDA clearance in its marketing. However, a search of the FDA’s 510(k) database does not turn up a clearance specific to a “Neurogenx” branded device for neuropathy treatment. A similarly named product, the NeuraGen 3D Nerve Guide Matrix, has FDA clearance, but that is a completely different device (a physical nerve repair implant used in surgery) made by a different company. FDA clearance of the general category of electrical stimulators does exist, but a 510(k) clearance means a device is substantially similar to something already on the market. It does not mean the FDA has evaluated whether the device effectively treats neuropathy.
Why Major Medical Groups Haven’t Endorsed It
The American Diabetes Association, the American Academy of Neurology, and other major organizations that publish neuropathy treatment guidelines have not included Neurogenx or “electronic signal treatment” in their recommendations. These guidelines are built on systematic reviews of the best available evidence, and the Neurogenx protocol simply hasn’t generated enough independent data to meet that threshold.
That doesn’t automatically mean it doesn’t work for anyone. It means the evidence isn’t strong enough, or independent enough, for the medical establishment to recommend it. Some patients do report meaningful relief. Whether that relief comes from the specific electrical signals, from the placebo effect (which is genuinely powerful for pain conditions), from the local anesthetic injections given alongside the treatment, or from some combination is impossible to determine without proper controlled trials.
Cost and Practical Concerns
Because insurance rarely covers Neurogenx, patients typically pay thousands of dollars out of pocket for a full treatment course. The company operates through franchise-style clinics, and patients often describe high-pressure sales environments with upfront payment expectations. For someone living with painful neuropathy who hasn’t found relief through standard treatments, this combination of hope and financial pressure deserves careful scrutiny.
Standard neuropathy treatments that are covered by insurance and supported by clinical guidelines include certain oral medications that calm overactive nerves, topical treatments, physical therapy, and in some cases, spinal cord stimulation for severe pain. These aren’t perfect either, and many neuropathy patients remain underserved by current options. That frustration is real, and it’s part of what makes treatments like Neurogenx appealing.
The Bottom Line on Legitimacy
Calling Neurogenx a “hoax” overstates it. The treatment is based on a real category of therapy that has shown genuine benefits in clinical research. But calling it “proven” or “clinically validated” also overstates it, because the specific Neurogenx protocol has not been tested in the rigorous, independent way that claim requires. What you’re paying a premium for is a branded version of electrical stimulation that lacks the independent evidence to justify its price or its marketing promises. The underlying science is real, but the gap between that science and what Neurogenx sells is wide enough to warrant serious caution before committing thousands of dollars.